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tion of dose distributions in lung tumours have been used to correct 
DVH’s planned in a static situation with pencil beam to a dynamic situ-
ation, considering breathing motions and a more correct dose calcula-
tion.
Results: At 17 mo. after end of study there is one local relapse alone 
and 7 cases displaying distant metastasis of which 2 are combined with 
regional failure (1 T1 and 6 T2). Grade 3 toxicity was seen in 3 patients 
with dyspnoe at 3, 6 and 9 months, not correlated with pneumonitis or 
ﬁbrosis. Spirometry data will be reported. Grade 3 toxicity with pain in 
the thorax was seen in 2 patients at 9 and 12 months not associated with 
rib fracture or tumor in proximity to the thoracic wall. 13/59 (22%) did 
not have any side effects. The most common side effect at 6 weeks was 
grade I skin reactions (19 patients with grade I and 4 with grade 2). At 
17 mo. after end of study 11 pts. had obtained CR, 30 showed PR and 8 
pats. had either local failure and/or distant metastases.
Conclusion: Using 15 x 3 Gy to stage I NSCLC results in acceptable 
early toxicity and favourable local control rate non inferior to what has 
been reported with fractionated RT.
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Background: For stereotactic lung irradiation, the dose is frequently 
prescribed to an isodose surface that encompasses the Planning Target 
Volume (PTV). This method is sensitive to incorrect modeling of the 
beam penumbra. Most dose calculation algorithms present in commer-
cially available treatment planning systems model the beam penumbra 
in water correctly. However, the beam penumbra in lung is much wider 
due to radiation and particle transport effects in low-density tissue, and 
is approximated only to a reasonable accuracy by few of the available 
calculation algorithms.
The aim of this study is to determine the effect of two dose calculation 
methods, with and without heterogeneity correction, on the prescribed 
dose to the tumor and the dose distribution in surrounding tissue. 
Methods: In our institute, stereotactic treatment plans for lung consist 
of 10 - 20 non-opposing photon beams (maximum energy 10 MV). 
Beam shapes and weights are optimized using Direct Machine Param-
eter Optimization (DMPO) available in the Pinnacle treatment planning 
system. A dose of 3 x 18 Gy is prescribed on the isodose surface that 
encompasses 95% of the PTV. Dose calculation is performed using 
the collapsed cone convolution/superposition algorithm, including all 
effects of tissue heterogeneity (heterogeneous plan). This algorithm is 
proven to be accurate in the presence of tissue heterogeneities through 
measurements in phantoms and comparison with Monte Carlo simula-
tions. To simulate an inaccurate dose calculation, we recalculated for 
15 patients the clinical treatment plan without heterogeneity corrections 
(homogeneous plan) while maintaining the number of Monitor Units 
(MU) from the clinical plan. The following dose parameters were com-
pared between the two plans: absolute isodose surface encompassing 
95% of the PTV (Dpres), relative maximum dose in the PTV (Dmax), 
ratio of the 50% prescription isodose volume to the PTV (R50), maxi-
mum dose 2 cm from PTV (D2cm), and percentage of lung volume 
receiving 20 Gy or more (V20).
Results: Compared to the heterogoneous plan, Dpres of the homoge-
neous plan increased from 54 Gy (by deﬁnition) to an average of 59 ± 
4 Gy (range 54 to 67 Gy). Due to increased attenuation and tightening 
of the beam penumbra in the homogeneous plan, Dmax was lower for 
the homogeneous plans (average 124% vs. 132%), while dose fall-off 
outside the PTV was steeper. The latter is reﬂected in a lower R50 for 
the homogeneous plans (4.2 ± 0.8) than for the heterogeneous plan (4.9 
± 1). D2cm and V20 were comparable for the two calculation methods 
(29 ± 2 Gy and 5 ± 2 %, respectively).
Conclusions: The absence of any heterogeneity correction (as required 
by some trial protocols) results in profound errors in dose distributions 
and the prescribed dose of stereotactic lung irradiation. Any dose calcu-
lation algorithm that does not predict penumbra broadening accurately 
(e.g. pencil beam algorithms), will result in errors in the calculated dose 
distributions which will affect the dose. The quality of the dose calcula-
tion algorithm is therefore an important parameter when comparing the 
local control and toxicity results of stereotactic studies in lung.
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Purpose: Assess the outcomes of non-small cell lung cancer (NSCLC) 
patients presenting with brain metastases (BM). 
Background: The brain is a common site of metastases and fre-
quently the ﬁrst site of treatment failure in non-small cell lung cancer 
(NSCLC). Patents presenting with synchronous BM may represent 
a unique population that could potentially beneﬁt from aggressive 
therapy. At this time, generally accepted treatment guidelines have not 
been established for these patients. 
Methods: Retrospective review of patients presenting with NSCLC 
with synchronous BM. Patients were assessed regarding treatment for 
both intracranial and intrathoracic disease. Aggressive treatment to 
the brain included either craniotomy or gamma knife radiosurgery and 
aggressive treatment to the primary lung cancer consisted of surgery, 
chemoradiation therapy or both.
Results: 75 NSCLC patients presented with synchronous BM treated 
between 1998-2002. 34 M: 41F, median age 60 years (40 -85), and 
median Karnofsky score 79 (40 - 100). Sixty-percent (45 pts) had 
extracranial metastases at the time of diagnosis, and 36 patients (48%) 
had a single brain metastasis. Treatment was considered aggressive 
(e.g. craniotomy or Gamma Knife radiosurgery) for CNS disease 43 
patients and for chest disease (e.g. surgery or chemoradiotherapy) in 
20 patients. With a median follow-up was 15 months (1-107), me-
dian survival was 8.4 months in the aggressive treatment group and 
7.7months in the “palliative” treatment group (p= 0.44). Ten patients 
survived more than 2 years (median 48 months for this cohort), and 
9/10 received aggressive CNS treatment while 5/10 recieved aggressive 
intrathoracic treatment. The patterns of relapse were similar in the ag-
gressive and palliative treatment groups. Twenty one patients recurred 
in the brain, (10/43 in aggressive treatment group, 11/36 palliative 
group). 9 patients recurred or demonstrated progressive disease in the 
lung (1/12 aggressive treatment group, 8/63 in non-aggressive group). 
In an analysis of prognostic factors including performance status, 
Copyright © 2007 by the International Association for the Study of Lung Cancer S753
Journal of Thoracic Oncology • Volume 2, Number 8, Supplement 4, August 2007  12th World Conference on Lung Cancer
number of intracranial lesions, presence of extra-cranial metastases and 
treatment approach, no variable signiﬁcantly inﬂuenced survival. How-
ever, aggressive salvage treatment with Gamma Knife radiosurgery did 
correlate with improved survival (Median survival 15.2 months after 
salvage radiosurgery, 8.2months following palliative whole brain radia-
tion therapy. P=0.03).
Conclusions: While the overall prognosis is poor for patients present-
ing with NSCLC and synchronous BM, our data suggests that a cohort 
of patients will be long-term survivors following aggressive treatment 
for intracranial disease. Aggressive salvage therapy for recurrent brain 
metastases also plays an important role in prolonging survival. Future 
studies are necessary to help identify patients most likely to beneﬁt 
from an aggressive approach. 
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Purpose: To evaluate retrospectively the effectiveness of re-irradiation 
in patients with non-metastatic non small cell lung cancer (NSCLC) at 
diagnosis who were previously irradiated with or without chemothera-
py and having local recurrence during follow-up.
Methods: In this study, 38 NSCLC patients having clinical ± radiologi-
cal progression retreated with hypofractionated radiotherapy between 
April 1992 and December 2006 were evaluated retrospectively. All 
patients were simulated before treatment. Radiotherapy ﬁeld covered 
the recurrent tumour with 1-2 cm safety margin. Two paralel or oblique 
opposite, isocentric ﬁelds were used while excluding spinal cord. 
The “adequate palliation” was deﬁned as more than 50% symptom 
palliation and “total/near total complete palliation” as 75-100%. The 
Log-rank method and Kaplan-Meier method was used for statistical 
analysis. 
Results: Median age was 58(33-80) years and all patients were 
male except 3. Median follow-up was 13.5 (4-65) months. The most 
frequent histology was squamous cell carcinoma (60.5%). Before 
reirradiation, chemotherapy was administrated to 9 patients without 
any response. Initially, median 30 Gy was given in median 10 frac-
tions. During reirradiation, a median total dose of 25 Gy (5 -30 Gy), in 
median 10 fractions (1-10) is delivered. The median interval between 
the initial radiation therapy and reirradiation was 35 (4-189) weeks. 
After hypofractionated reirradiation “adequate palliation” is obtained 
in 62.5% of the patients with cough, in 53% of patients with dispnea 
and in 50% of patients with hemoptysis and chest pain. “ Total / near 
total palliation” was noted in 35.6% of patients. After reirradiation, the 
median survival time was 11(1-237) weeks. The overall survival after 
initial diagnosis were 57.8% at 1 year and 28.8 % at 2 years and after 
reirradiation it was 8.7 % and 5.8 % respectively. In univariate analysis; 
age, tumour size, tumor location, interval between initial irradiation and 
reirradiation were evaluated for overall survival. A signiﬁcant survival 
advantage is seen in patients having an interval of more than 35 weeks 
(p=0.000). None of the patients had grade III-IV EORTC / RTOG side 
effects.
Conclusion: In non-metastatic NSCLC patients, reirradiation can 
provide adequate symptom relief. With 25 Gy hypofractionated reir-
radiation, total or near total palliation of symptoms can be obtained in 
almost one third of the patients having symptomatic local recurrence. 
Reirradiation of recurrent primary tumour can be used to improve the 
quality of life and prolong survival. Especially patients having long 
interval after initial radiotherapy can beneﬁt from this approach. How-
ever, studies including more patients are needed to prove the effective-
ness and economical advantages of this treatment modality.
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Purpose: To determine effectiveness of hypofractionated radiotherapy 
with or without cisplatin in the treatment of patients with non small cell 
lung cancer (NSCLC).
Methods: In this retrospective study, including the period July 1999-
September 2005, we evaluated 43 patients who were ineligible for 
multiagent chemotherapy with KPS ≥70 and tumour size preventing 
radical treatment. Radiotherapy, which involved primary tumour and 
metastatic lymph nodes, was given in 15 fractions over 3 weeks up 
to 45 Gy. Cord sparing was performed at 30 Gy (HIPO). Weekly 30 
mg/m2 cisplatin was concomitantly given with radiotherapy in appro-
priate patients (HIPOP). Kaplan Meier method was used for statistical 
analyses. 
Results: Median age was 58(36-80). The most frequent histology was 
squamous cell carcinoma (49%). There were 1(2%);8(19%);25(58%) 
and 9(21%) patients with stage IIB,IIIA,IIIB and stage IV respectively. 
The tumour size was ≥5 cm in 79% of patients. Neoadjuvant cisplatin-
based chemotherapy was given to 18 patients. There were 21 and 22 
patients in HIPO and HIPOP scheme, respectively. The median follow-
up was 9(1-24) months. Preradiotherapy symptoms were cough (49%), 
chest pain (49%), dyspne (37%) and hemoptysis (26%). According 
to treatment scheme, palliation rates were: 60%/100% in hemoptysis; 
71%/100% in dyspnea; 80%/91% in cough and 86%/86% in pain for 
HIPO/HIPOP. One-year overall survival (OS) was 67% and 45% for 
HIPOP and HIPO, respectively. No patients had severe RTOG grade 
III-IV side effects. 
Conclusion: HIPO/HIPOP schemes seem safe and effective modalities 
in locally advanced NSCLC patients who are not candidates for radical 
treatment. 
* This abstact is also presented in Balkan Union of Oncology 2006 
Meeting.
